Currently the reimbursement of personalized medicines is not coupled with that of the accompanying biomarker which often leads to a delay in reimbursement of the predictive tests as compared to the personalized medicine. To better align reimbursement of the medicine and the predictive test, a coupled reimbursement procedure[1],[2] will be created that will allow a monthly update of reimbursed personalized medicines and their corresponding predictive test, and as such will be flexible enough to adjust for the rapid evolving field...